Metastatic CRPC Patient Identification

Metastatic CRPC Is Common

Most men with castrate-resistant prostate cancer (CRPC) will eventually develop metastatic disease.1-3

Learn more about diagnosing mCRPC

PROVENGE Treatment Window

In the newly metastatic CRPC patient who is asymptomatic or minimally symptomatic, there’s a PROVENGE window.

Learn more about the PROVENGE treatment window

For the Newly Metastatic CRPC Patient

61% of men are PROVENGE-eligible at diagnosis of metastatic CRPC.4

Identify PROVENGE patients

Discuss PROVENGE With Your Patients

Help your patients understand treatment with PROVENGE.

Talk with your patients

REFERENCES:
  1. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Current Oncology. 2010;17(S2):S72-S79.
  2. National Comprehensive Cancer Network. Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. Version 1.2013. 1/20/13.
  3. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-1192.
  4. Data on file. Dendreon Corporation.